RAPP
Rapport Therapeutics, Inc.
27.02
+1.06 (+4.08%)
52w low 22.06
52.93 high
16.1% of range
Financial Analysis
| (USD) | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 | Trend |
|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 20.00M | 0.00 | 0.00 | |
| Operating Expenses | 29.99M | 38.51M | 44.22M | 60.81M | 44.09M | |
| R&D | 22.28M | 30.26M | 32.72M | 51.41M | 34.32M | |
| SG&A | 7.71M | 8.25M | 11.50M | 9.39M | 9.77M | |
| Operating Income | -29.99M | -38.51M | -24.21M | -60.81M | -44.09M | |
| EBITDA | -29.73M | -38.24M | -23.99M | -60.59M | -43.89M | |
| Pretax Income | -26.93M | -33.76M | -19.86M | -56.62M | -40.23M | |
| Net Income | -26.93M | -33.76M | -19.86M | -56.62M | -40.23M | |
| EPS Diluted | -0.71 | -0.72 | -0.42 | -1.19 | -0.84 | |
| Diluted Shares | 37.93M | 46.98M | 47.24M | 47.47M | 47.77M |
Revenue CAGR
--
Net Income CAGR
--
EPS CAGR
--
FCF CAGR
--
Revenue YoY
--